Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
IL-6 and CXCL8 mediate osteosarcoma-lung interactions critical to metastasis
Amy C. Gross, Hakan Cam, Doris A. Phelps, Amanda J. Saraf, Hemant K. Bid, Maren Cam, Cheryl A. London, Sarah A. Winget, Michael A. Arnold, Laura Brandolini, Xiaokui Mo, John M. Hinckley, Peter J. Houghton, Ryan D. Roberts
Amy C. Gross, Hakan Cam, Doris A. Phelps, Amanda J. Saraf, Hemant K. Bid, Maren Cam, Cheryl A. London, Sarah A. Winget, Michael A. Arnold, Laura Brandolini, Xiaokui Mo, John M. Hinckley, Peter J. Houghton, Ryan D. Roberts
View: Text | PDF
Research Article Oncology

IL-6 and CXCL8 mediate osteosarcoma-lung interactions critical to metastasis

  • Text
  • PDF
Abstract

Osteosarcoma (OS), a malignant tumor of bone, kills through aggressive metastatic spread almost exclusively to the lung. Mechanisms driving this tropism for lung tissue remain unknown, though likely invoke specific interactions between tumor cells and other cells within the lung metastatic niche. Aberrant overexpression of ΔNp63 in OS cells directly drives production of IL-6 and CXCL8. All these factors were expressed at higher levels in OS lung metastases than in matched primary tumors from the same patients. Expression in cell lines correlated strongly with lung colonization efficiency in murine xenograft models. Lentivirus-mediated expression endowed poorly metastatic OS cells with increased metastatic capacity. Disruption of IL-6 and CXCL8 signaling using genetic or pharmaceutical inhibitors had minimal effects on tumor cell proliferation in vitro or in vivo, but combination treatment inhibited metastasis across multiple models of metastatic OS. Strong interactions occurred between OS cells and both primary bronchial epithelial cells and bronchial smooth muscle cells that drove feed-forward amplification of IL-6 and CXCL8 production. These results identify IL-6 and CXCL8 as primary mediators of OS lung tropism and suggest pleiotropic, redundant mechanisms by which they might effect metastasis. Combination therapy studies demonstrate proof of concept for targeting these tumor-lung interactions to affect metastatic disease.

Authors

Amy C. Gross, Hakan Cam, Doris A. Phelps, Amanda J. Saraf, Hemant K. Bid, Maren Cam, Cheryl A. London, Sarah A. Winget, Michael A. Arnold, Laura Brandolini, Xiaokui Mo, John M. Hinckley, Peter J. Houghton, Ryan D. Roberts

×

Figure 3

Combined disruption of IL-6 and CXCL8 signaling reduces or eliminates metastatic lung colonization.

Options: View larger image (or click on image) Download as PowerPoint
Combined disruption of IL-6 and CXCL8 signaling reduces or eliminates me...
Mice inoculated with 1 × 106 luciferase-expressing OS-17 cells were treated with pharmacologic inhibitors of IL-6 (sc144, inhibitor of IL-6ST), CXCL8 (DF2156A, inhibitor of CXCR1 and -2), or both. (A) Bioluminescent imaging completed at 28 days after inoculation. (B) Gross appearance of representative lung blocks taken from the mice identified with red frames in A at the time of euthanasia (endpoint criteria, or day 200 for mice 1 and 9 of combined treatment group) shows no microscopic evidence of tumor in long-term survivors. This included some mice, such as mouse 10 of the combined treatment group (endpoint at day 72) that showed response at early time points, but subsequently developed metastasis. Scale bar: 2 mm. (C) Quantification of the lung-field bioluminescence from day 14 (n = 10 mice per group). (D) Survival analysis of the mice shown in A. As noted, treatment continued until day 42, then was stopped. Mice that received combination therapy experienced significantly better outcomes than those who received no treatment or treatment with only 1 inhibitor (n = 10 mice per group, P value in comparison to vehicle control). (E) Validation studies confirm the results found in A. Mice surviving beyond 200 days were euthanized. Mice that died during the study, but had no evidence of metastatic tumor burden on necropsy (n = 3) were censored in this analysis (n = 25 mice per group). No Tx, no treatment. **P < 0.01; ****P < 0.0001 by 1-way ANOVA with Tukey’s post hoc test (C) or Mantel-Cox log-rank test (D and E).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts